ReviewMicroorganisms2025
Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Unveiling the Origin of Regioselectivity in Iron(III)-Promoted Friedel-Crafts Synthesis of Cannabinoids: Theoretical Studies and Synthetic Applications.The Journal of organic chemistry · 2026Article
- Antimicrobial Agents in Fibrous Materials: A Comprehensive Review of Natural, Inorganic, and Organic Systems.Materials (Basel, Switzerland) · 2026Review
- Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation.International journal of molecular sciences · 2026Article
- Structure-Activity Relationships of Cannabigerol and Cannabigerolic Acid Derivatives as Antibacterial Agents against Gram-Positive Bacteria.ACS omega · 2026Article
- Efficacy of Cannabidiol in Reducing Virulence ofInternational journal of molecular sciences · 2026Article
- Cannabidiol (CBD) InhibitsInternational journal of dentistry · 2026Article
- Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.BMC complementary medicine and therapies · 2025Article
- A Stroll Through Saffron Fields, Cannabis Leaves, and Cherry Reveals the Path to Waste-Derived Antimicrobial Bioproducts.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Identification of cannabinoid-sensitive and -resistant oral bacteria.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the scenario of fighting bacterial resistance to antibiotics, natural products have been extensively investigated for their potential antibacterial activities. Among these, cannabinoids-bioactive compounds derived from cannabis-have garnered attention for their diverse biological activities, including anxiolytic, anti-inflammatory, analgesic, antioxidant, and neuroprotective properties. Emerging evidence suggests that cannabinoids may also possess significant antimicrobial properties, with potential applications in enhancing the efficacy of conventional antimicrobial agents. Therefore, this review examines evidence from the past five years on the antimicrobial properties of cannabinoids, focusing on underlying mechanisms such as microbial membrane disruption, immune response modulation, and interference with microbial virulence factors. In addition, their synergistic potential, when used alongside standard therapies, underscores their promise as a novel strategy to address drug resistance, although further research and clinical trials are needed to validate their therapeutic use. Overall, cannabinoids offer a promising avenue for the development of innovative treatments to combat drug-resistant infections and reduce the reliance on traditional antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.